• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Athira Pharma Inc.

    11/7/24 1:15:00 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    SC 13G 1 atha13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

     Athira Pharma, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value
    (Title of Class of Securities)
     
     04746L104
    (CUSIP Number)
     
    November 1, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     2,233,167
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     2,233,167
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     2,233,167
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.8%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     
    1
    NAMES OF REPORTING PERSONS
     
     
     Braden M Leonard
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     251,278
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     2,233,167
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     251,278
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     2,233,167
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     2,484,445
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     6.5%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     

    Item 1(a). Name of Issuer:

     Athira Pharma, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     18706 North Creek Parkway, Suite 104 Bothell, WA 98011

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2, Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

     04746L104


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 2,484,445


    (b) Percent of class: 6.5


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 251,278


    (ii) Shared power to vote or to direct the vote: 2,233,167

      (iii) Sole power to dispose or to direct the disposition of: 251,278

      (iv) Shared power to dispose or to direct the disposition of: 2,233,167
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 7, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member of GP
     
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

    Get the next $ATHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fluke John M Jr

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:37:07 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Panzara Michael A.

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:36:21 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Romano Kelly A

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:35:41 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care